Investigating the effects of age, IQ, dosing, and anthropometric measures on the treatment persistence in long-term methylphenidate use
- 24 August 2022
- journal article
- research article
- Published by Taylor & Francis Ltd in Nordic Journal of Psychiatry
- Vol. 77 (4), 345-351
- https://doi.org/10.1080/08039488.2022.2112284
Abstract
This study aimed to determine anthropometric and clinical correlates of persistence to methylphenidate (MPH) treatment in Turkish youth with attention-deficit hyperactivity disorder (ADHD). Data from medical records of 518 children and adolescents with ADHD were recorded between March 2012 and January 2022. Clinical variables of patients persistent to MPH ≥ 2 years were compared with those of the non-persistent group. Children and adolescent age groups were compared using Kaplan–Meier estimates for treatment drop-outs. Cox regression analysis until the treatment drop-out was implemented to calculate hazard ratios (HRs) for gender, age, full-scale IQ, and anthropometric measures. Weight, height, and body mass index (BMI) z-scores were calculated per national guidelines. Persistent and non-persistent study groups had similar full-scale IQ, weight, height, and BMI z-scores at treatment onset. The mean MPH dose was significantly higher in the persistent group compared to the non-persistent counterparts (31.43 ± 10.70 vs. 24.28 ± 9.60 mg/d, p < 0.001, d = 0.70). Compared to children, the adolescents showed earlier treatment drop-outs in males (p < 0.001) but not in females (p = 0.110). Younger age showed a positive effect on treatment persistence. Conversely, baseline BMI and IQ scores were not associated with long-term persistence. Our study demonstrated lower daily doses and older age-onset were associated with early drop-outs in MPH treatment. These findings supported the notion that effective dosing strategies at younger ages could increase the sustainability of the treatment with MPH in the Turkish population.Keywords
This publication has 47 references indexed in Scilit:
- Enhancing ADHD Medication Adherence: Challenges and OpportunitiesCurrent Psychiatry Reports, 2013
- Comorbidities in ADHD children treated with methylphenidate: a database studyBMC Psychiatry, 2013
- Rates of undiagnosed attention deficit hyperactivity disorder in London drug and alcohol detoxification unitsBMC Psychiatry, 2012
- Evaluation of attitudes towards treatment in adolescents with attention deficit hyperactivity disorder (ADHD)European Child & Adolescent Psychiatry, 2012
- Parent Perspectives on the Decision to Initiate Medication Treatment of Attention-Deficit/Hyperactivity DisorderJournal of Child and Adolescent Psychopharmacology, 2012
- Differential Effects of Predictors on Methylphenidate Initiation and Discontinuation Among Young People with Newly Diagnosed Attention-Deficit/Hyperactivity DisorderJournal of Child and Adolescent Psychopharmacology, 2011
- Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the NetherlandsADHD Attention Deficit and Hyperactivity Disorders, 2010
- Understanding survival analysis: Kaplan-Meier estimateInternational Journal of Ayurveda Research, 2010
- An Analysis of Patient Adherence to Treatment During a 1-Year, Open-label Study of OROS® Methylphenidate in Children With ADHDJournal of Attention Disorders, 2007
- Determinants of compliance with methylphenidate therapy in childrenActa Paediatrica, 2006